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Abstract
The prevalence of human immunodeficiency virus type 1 (HIV-1) is highest among men who have sex with
men (MSM) in Jamaica but no genotypic data are available on the virus strains that are responsible for the
epidemic among this key population. HIV-1 polymerase ( pol) genes from 65 MSM were sequenced and used to
predict drug resistance mutations. An HIV drug resistance prevalence of 28% (minimum 13%) was observed
among this cohort, with the most frequent mutations conferring resistance to efavirenz, nevirapine, and lami-
vudine. Phylogenetic analysis of the sequences revealed 10 times the number of linked HIV infections among
this cohort than respondent reporting. HIV treatment and prevention efforts in Jamaica could benefit signifi-
cantly from Pol genotyping of the HIV strains infecting socially vulnerable MSM prior to initiating anti-
retroviral therapy (ART), as this would guide suppressive ART and unearth HIV transmission clusters to enable
more effective delivery of treatment and prevention programs.
The human immunodeficiency virus (HIV) infectsapproximately 35 million people globally and accounted
for 1.6 million deaths in 2012. The Caribbean region has an
HIV prevalence of 1%, which is the second highest after sub-
Saharan Africa. The severity of the epidemic varies among
individual countries in the region, as Cuba has the lowest HIV
prevalence in the Caribbean (<0.1%) while Bahamas has the
highest prevalence of 3.3%.1 Heterosexual transmission ac-
counts for the greatest number of new HIV cases globally,
but men who have sex with men (MSM) often have a higher
HIV prevalence than other population groups.2 In Jamaica,
HIV prevalence among the general adult population is 1.8%
while the HIV prevalence among MSM is estimated as 38%.1
Adverse social experiences such as rape, incarceration,
homelessness, and unemployment contribute to the high HIV
prevalence among Jamaica’s MSM.3
In mixed HIV epidemics, such as Jamaica’s, key popula-
tions must be specially targeted in order to achieve a signif-
icant reduction in population level HIV incidence. The World
Health Organization recommends scaling up the use of an-
tiretroviral (ARV) drugs for treating HIV-infected individu-
als and preventing transmission.4 However, scaling up of
antiretroviral use necessitates increased surveillance of
HIV drug resistance.4,5 A transmitted drug resistance of 12–
29% has been reported for HIV-infected heterosexuals in
Jamaica,6,7 but estimates of drug resistance among the is-
land’s MSM is lacking. Integrating the use of ARV drugs in
HIV prevention programs for Jamaica’s MSM should be
considered since HIV prevalence among this risk group has
remained high since 1995, despite HIV educational inter-
ventions for behavior change.8 Knowledge of the drug sus-
ceptibility of HIV strains in the target population could
enable the most effective implementation of any ARV-based
prevention strategy; consequently, this should be obtained for
HIV strains infecting MSM in Jamaica.
Jamaica’s HIV response scarcely uses genotypic data on
the circulating HIV strains, despite evidence showing its
usefulness in guiding effective antiretroviral therapy and
more recent demonstrations that it can reveal transmission
events and therefore sexual networks.9 Since sequencing
of the HIV polymerase gene can identify both drug resis-
tance and HIV transmission networks, it is a valuable tool for
understanding epidemics among stigmatized populations,
such as MSM, as well as sex workers and their clients.10
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Identifying and understanding HIV transmission networks
can support the successful design and implementation of
treatment strategies.
This study investigates the polymerase gene of HIV strains
infecting MSM in Jamaica to detect drug resistance muta-
tions and identify transmission networks among this key
population, so as to gain insights that could contribute to the
development of effective interventions to reduce HIV trans-
mission in Jamaica.
Plasma was previously collected from HIV-positive MSM
who participated in a survey of Men’s Health in Jamaica from
2010 to 2011. Participant recruitment, sample collection,
participant characteristics, and ethical approval were previ-
ously described.3
RNA was extracted from plasma of 141 HIV-seropositive
MSM using the QiaAmp Viral RNA Mini kit (Qiagen) ac-
cording to the manufacturer’s instructions. The RNA was
reverse transcribed using SuperScript III RT (Life Technol-
ogies) and used as template in nested PCR targeting the
complete protease (PR) and the majority of the reverse
transcriptase (RT) gene. Nested PCR was done using the
Expand High Fidelity PCR System (Roche).
First round primers were MPOLUP3 (5¢-TTCAGAGCAG
ACCAGAGCCAACAGC) and BPOLDN1 (5¢-ATAAATCT
GACTTGCCCAATTCAATTTTCC) and second round
primers were BPOLUP4 (5¢-ACAACAACTCCCTCTCAG
AAGCAGG) and CPOLDN2 (5¢-CCACTAACTTCTGTAT
ATCATTGACAGTCC). The second round primers plus two
internal primers, MBP006 (5¢-CCTCCTTTTCCATTTCTG)
and MBP008 (5¢-CAGAAATGGAAAAGGAAG), were
used for population sequencing through the University
of North Carolina Genomic Analysis Core Facility. When
necessary, two other internal primers were also used,
MBP001 (5¢-CTAATACTGTACCTATAGC) and MBP010
(5¢-TCAAAGTAAGACAGTATGATC). Sequences were
aligned and assembled into a single contiguous consensus for
each individual using Sequencher software (Gene Codes
Corporation). The subtype and drug resistance profile of the
HIV PR/RT sequences were determined in silico using the
REGA Subtyping tool (www.bioafrica.mrc.ac.za/rega-geno
type/html/subtypinghiv.html) and the Calibrated Population
Resistance (http://cpr.stanford.edu/cpr/index.html) tool, re-
spectively. The two most identical homologs to each of the
Jamaican MSM sequences were retrieved from the GenBank
database.
A multiple alignment of the Jamaican MSM sequences and
their homologs was constructed and included all GenBank
HIV-1 sequences from Jamaica, the HXB 2 subtype B ref-
erence sequence, and consensus sequences from other HIV
subtypes. Codon alignment of the sequences was performed
with the Codon Alignment v.1.1.0 tool (www.hiv.lanl.gov/
content/sequence/CodonAlign/codonalign.html) and the
multiple alignment used for maximum likelihood phyloge-
netic reconstruction with a general time reversible model.
The original alignment was stripped of 36 protease and 32
reverse transcriptase codons associated with drug resis-
tance5,11 and phylogenetic reconstruction was repeated on
this edited alignment. Bootstrap analysis was performed on
1,000 replicates to assess nodal support. Putative transmis-
sion clusters were defined as ‡2 closely related sequences
(£1.5% mean intracluster difference in genetic distance) with
high bootstrap support (‡98%) at the node-defining clade.
The HIV-1 polymerase (Pol) gene segment spanning co-
ordinates 2252–3252 of HXBc2 and containing the com-
plete 99 codons of PR and the first 234 codons of RT was
successfully amplified from 46% (65/141) of samples and
deposited in GenBank (accession nos.: KP159440 and
KP159449–KP159508). All 65 sequences were HIV-1 sub-
type B and had an average sequence distance of 2.6% (range
0–5.4%).
The antiretroviral therapy (ART) treatment status of the
study participants was not ascertained in the survey; how-
ever, major drug resistance mutations (DRMs) were observed
in 28% (18/65) of the sequences. The prevalence of drug
resistance in the entire HIV-positive MSM dataset will be no
less than 13% (18/141). All 18 sequences with major DRMs
were predicted to be resistant to nonnucleoside reverse
transcriptase inhibitors (NNRTIs), with 67% (12/18) having
the K103N mutation that gives high level resistance to ne-
virapine and efavirenz.12 Dual resistance to both nucleoside
reverse transcriptase inhibitors (NRTIs) and NNRTIs was
predicted for 55% (10/18) of samples showing DRMs, and
M184V, which confers high level resistance to lamivudine,12
was the most common NRTI mutation in the dataset (Table
1). From the survey, MSM reported characteristics such as
age, sexual orientation, socioeconomic status, literacy, ever
raped, marital status, and number of partners. There was no
significant difference in the surveyed characteristics between
MSM who had drug-resistant HIV (drHIV) and MSM with-
out drHIV or HIV-seropositive MSM from whom virus am-
plification failed.
Phylogenetic analyses with the DRM stripped alignment
revealed that 31% (20/65) of the MSM HIV-1 sequences
formed eight clusters of two or more sequences with 100%
bootstrap support and a mean intracluster genetic dis-
tance £ 1.5% (Fig. 1). Cluster H (Fig. 1) contained a Jamaican
reference sequence that was isolated from a Jamaican MSM
in 2007; this was the only cluster containing any reference
sequence. Cluster G, which is a dyad, is the only cluster
containing DRM. Both members of Cluster G had the K103N
mutation and one member additionally had M41L, M184V,
and T215Y, which provide resistance to NRTIs. The majority
(80%) of MSM whose HIV sequences clustered were 16–24
years old while only 44% of men whose sequences remained
unclustered were in this younger age group. Neither age nor
any of the other surveyed characteristics were statistically
different between clustered and unclustered HIV sequences.
Table 1. Frequency of Different Types
of Drug Resistance Mutations Among Men
Who Have Sex with Men in Jamaica
NNRTI N (%) NRTI N (%)
K103N 12 (67%) M184V 9 (50%)
Y181C 5 (28%) T215Y 4 (22%)
G190A/S 2 (11%) M41L 4 (22%)
K101E 1 (6%) K65R 2 (11%)
Y188L 1 (6%) L74I 2 (11%)
P225H 1 (6%) K70R 1 (6%)
M230L 1 (6%) L210W 1 (6%)
NNRTI, nonnucleoside reverse transcriptase inhibitors; NRTI,
nucleoside reverse transcriptase inhibitors.
842 COLLINS-FAIRCLOUGH ET AL.
In this study, the majority (54%) of samples indicated to be
HIV positive based on antibody tests failed to generate am-
plicons in PCR. Control reactions confirm the integrity and
viability of the RNA extraction and PCR reactions. It is
therefore likely that the samples are at fault; however, limited
sample volumes prevented further investigation of this. The
ART status of the study participants was not ascertained
during the survey, but 6.4% (9/141) of the HIV-seropositive
survey participants reported never receiving an HIV test
before, indicating that the overwhelming majority of these
men could have been aware of their HIV-positive status. If
participants were receiving ART, then this could have sup-
pressed their circulating HIV RNA to undetectable levels and
consequently contribute to 54% of the samples failing to
produce amplicons.
The 28% drug resistance prevalence observed among this
sample set is consistent with that reported for treatment-
experienced (35%) and treatment-naive (29%) heterosexual
Jamaicans6,7 and higher than the 7% reported in Cuba.13
None of the samples had major protease inhibitor mutations,
in contrast to findings among a Jamaican heterosexual co-
hort.7 The epidemiology survey through which these samples
were obtained did not ask respondents to self-report whether
they previously received ARV treatment; it is therefore un-
clear whether the 26% prevalence of drug resistance is ac-
quired, transmitted, or due to both. The M184V mutation
readily emerges during suboptimal lamivudine treatment, but
reduces the ability of the virus to replicate. The result is that
M184V is poorly maintained in the absence of lamivudine,
such as during primary infection, soon after HIV transmis-
sion.14 M184V occurred in 50% of the drug-resistant se-
quences obtained. Considering the poor replicative fitness of
M184V, men possessing viruses with this mutation are more
likely to have been drug exposed rather than acquiring these
mutant HIV strains by horizontal transmission. Efavirenz,
nevirapine, and lamivudine are among the ARV drugs used in
first line ART in Jamaica.15
The presence of resistance mutations against efavirenz,
nevirapine, and lamivudine suggests that similar to the het-
erosexual population, a subset of MSM will fail or are failing
first line antiretroviral therapy. Individual ART failure pre-
vents the realization of population level protection against
HIV and erodes the future usefulness of ARV drugs. The
inconsistent condom use reported by MSM in general8 sug-
gests the likelihood for transmission of resistant strains.
There is therefore an urgent need for Jamaica to initiate drug
resistance surveillance.
This study provides insight into drug resistance among
Jamaican MSM and provides the first look at HIV drug re-
sistance among MSM in a Caribbean nation other than Cuba.
The detection of any statistically significant behavioral or
demographic association with drug resistance or clustering
was constrained by the small sample size that resulted from
only 46% (65/141) of the PR/RT being amplifiable from the
HIV-seropositive MSM in the survey. There is strong social
stigma against MSM in Jamaica, which drives the HIV epi-
demic underground and contributes to the spread of HIV. The
men from whom these samples were obtained are unlikely to
be representative of the MSM population as a whole because
they were primarily of lower socioeconomic status with a
history of adverse life events and had high rates of transac-
tional and commercial sex.8 Consequently, the 26% drug
FIG. 1. Maximum-likelihood phylogenetic tree of 65
study sequences obtained from Jamaican men who have sex
with men from 2010 to 2011, with closely related reference
sequences available in GenBank (references sampled in
Jamaica are indicated in blue). Study sequences (n = 21;
30%) were identified in eight transmission clusters (indi-
cated by gray shading and letters A–H).
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resistance prevalence among this sample set is not general-
izable to the wider HIV-seropositive MSM community in
Jamaica. Nevertheless, the drug resistance profiles unveiled
here suggest an urgent need to scale up HIV testing and HIV
drug resistance monitoring to acquire concrete insights that
can lead to effective prevention and treatment of HIV in-
fection among MSM.
Phylogenetic analyses revealed that 31% of the sequences
obtained in this study clustered closely with at least one other
study sequence, which is similar to other studies with con-
venience-based samples.9 Phylogenetic clusters with low
genetic distance are likely to represent linked transmission,
especially when DRM sites are excluded from analyses9 and
unsampled third parties may be part of the transmission
chain. From the survey, 2.9% (2/70) of men from whom HIV
sequences were obtained reported having been invited into
the study by a sexual partner. Despite the stringent criteria
utilized in demarcating clusters (£0.015 genetic distance and
100% bootstrap support), the phylogenetic analyses detected
10 times the number of linked HIV transmissions than that
reported by MSM. The discrepancy between the two methods
may arise from respondent misreporting, anonymous part-
ners, indirect transmissions, as well as the fact that current
sexual partners are not necessarily the transmission partners
and highlights a limitation when using sexual contact re-
porting to reconstruct transmission networks. Jamaica could
benefit greatly by using HIV Pol genotyping for both drug
resistance surveillance as well as identifying transmission
clusters. Transmission clusters could then be characterized to
better understand the epidemic and design appropriate strat-
egies for improving HIV treatment and prevention.
This study suggests that the prevalence of HIV drug re-
sistance among MSM in Jamaica is comparable to that among
the general population. It is therefore necessary to concom-
itantly scale up genotypic testing of HIV strains among MSM
and the general population for effective HIV treatment and
prevention to ensure the continued success of Jamaica’s HIV
response.
Sequence Data
Sequences generated in this study were deposited in the
NCBI GenBank database under the accession numbers
KP159440 and KP159449–KP159508.
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